PRODUCT CODE: ET7106-72

Recombinant ADAR Monoclonal Antibody (ET7106-72)

  • Recombinant

Applications

  • WB

  • ICC

  • IF

  • IHC-P

REACTIVITY

  • Human

Western blot analysis of ADAR on SiHa cell using anti-ADAR antibody at 1/500 dilution.
  • Western blot analysis of ADAR on SiHa cell using anti-ADAR antibody at 1/500 dilution.
  • ICC staining ADAR in Hela cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
  • Immunohistochemical analysis of paraffin-embedded human colon cancer tissue using anti-ADAR antibody. Counter stained with hematoxylin.
  • Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-ADAR antibody. Counter stained with hematoxylin.
  • Immunohistochemical analysis of paraffin-embedded human lung cancer tissue using anti-ADAR antibody. Counter stained with hematoxylin.
  • Immunohistochemical analysis of paraffin-embedded human pancreas tissue using anti-ADAR antibody. Counter stained with hematoxylin.
Western blot analysis of ADAR on SiHa cell using anti-ADAR antibody at 1/500 dilution.

Applications

  • WB

  • ICC

  • IF

  • IHC-P

REACTIVITY

  • Human

SPECIFICATIONS

Product Type

Recombinant Rabbit monoclonal primary

Product Name

Recombinant ADAR Monoclonal Antibody (ET7106-72)

Immunogen

Recombinant protein

Host

Rabbit

Positive Control

Hela, human lung cancer tissue, human colon cancer tissue, human kidney tissue, human pancreas tissue, SiHa.

Conjugation

Unconjugated

Clonality

Monoclonal

Clone Number

JU99-33

PROPERTIES

Form

Liquid

Storage Condition

Store at +4C after thawing. Aliquot store at -20C or -80C. Avoid repeated freeze / thaw cycles.

Storage Buffer

1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.

Concentration

1 ug/ul

PURIFICATION

Protein A purified.

MOLECULAR WEIGHT

136 kDa

Isotype

IgG

APPLICATION DILUTION

  • WB

  • 1:500-1:2,000

  • ICC

  • 1:50-1:200

  • IHC-P

  • 1:50-1:200

TARGET

UNIPROT #

PROTEIN NAME

Double-stranded RNA-specific adenosine deaminase

GENE NAME

ADAR

SYNONYMS

DRADA, p136, IFI-4, ADAR, ADAR1, DSRAD, G1P1, IFI4

TISSUE SPECIFICITY

Ubiquitously expressed, highest levels were found in brain and lung. Isoform 5 is expressed at higher levels in astrocytomas as compared to normal brain tissue and expression increases strikingly with the severity of the tumor, being higher in the most aggressive tumors.

POST-TRANSLATIONAL MODIFICATION

Sumoylation reduces RNA-editing activity.

SUBCELLULAR LOCATION

[Isoform 1]: Cytoplasm. Nucleus. Note=Shuttles between the cytoplasm and nucleus. Nuclear import is mediated by TNPO1.; [Isoform 5]: Cytoplasm. Nucleus. Nucleus, nucleolus. Note=Predominantly nuclear but can shuttle between nucleus and cytoplasm. TNPO1 can mediate its nuclear import whereas XPO5 can mediate its nuclear export.

FUNCTION

Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication.